New Zealand has been here before. Every major technological shift in history has followed the same pattern: early optimism, followed by concern, debate — and delay. From the industrial revolution to vaccines, antibiotics, biotechnology and now artificial intelligence, innovation has always been met with hesitation.
This tension is not new. It is human.
At the heart of every technological shift are not machines or science - but people reacting to change.
That is why lived experience matters — as does being heard, having access to real‑world evidence, and the knowledge needed to make informed choices. Listening to the lessons of those who have come before us.
New Zealand once again stands at a familiar crossroads - debating whether — and how — to embrace innovation like biotechnology and artificial intelligence. This debate is often framed as technical. In reality, it is deeply human.
The reality is - much of what is being registered in New Zealand as “new” in 2026 is not new at all. A fodder beet treatment approved here in March 2026 has been used in the United States since 1996 — three decades of real‑world evidence, not experimental science. That not innovation - it’s delay.
Since the first recombinant DNA work in 1973, biotechnology has more than 50 years of international research, use and real‑world monitoring to shape these tools. Embedded in farming systems and manufacturing processes across multiple countries, governed by regulatory frameworks shaped by decades of real‑world experience.
The world - and the technology - have moved on. As a small country at the edge of the world, the question is simple - do we want supply or not?
Risk is real and needs careful consideration — especially where New Zealand faces genuinely unique circumstances.
But that requires transparency about what those circumstances are, and accountability for how they shape decisions. Risk is never purely technical. It is shaped by fear, experience, trust — and failure.
New Zealand has scar tissue, as do all small exporting nations. Scar tissue protects by stiffening — and in doing so, steals the ability to bend. This is not an academic problem waiting for a technical fix; it is a human one requiring confidence and context
History also teaches us that no single solution works in isolation for innovation.
Vaccines, one of medicine’s greatest achievements, are only effective when supported by surveillance, communication, informed choices and public confidence.
Antibiotics remain essential but work best alongside prevention and good management. Evidence‑based practice refines these tools — it doesn’t replace them.
Biological products are not a panacea, their use depends on timing, weather and handling. To be biological is to adapt. As climate variability increases, uncertainty increases with it. International experience consistently shows these products are most effective when used alongside chemistry, genetics, agronomy and sound management — not as replacements.
History is clear: layered approaches outperform one‑size‑fits‑all thinking.
In an increasingly unstable world, resilient systems resemble the Swiss cheese model. Multiple independent lines of defence working together. Diversity slows resistance. Local context improves outcomes. Commercial reality tempers ideology. Choice strengthens systems.
So, what does all this mean right now for New Zealand?
Global supply chains respond to signals, not sentiment. History has shown us this again and again.
R&D companies prioritise markets that value their full product portfolios, not fragments of them. Rising costs and regulatory uncertainty are already shaping decisions. Some companies have walked away; others are quietly pulling back.
For New Zealand, the question is no longer “Do we register these products?” but “Do we supply at all?”
Farmers, growers and veterinarians are asking the same thing: will there be reliable supply, genuine choice and affordable options?
Clear, evidence‑based conversations grounded in decades of global experience reduce uncertainty. Zero risk is impossible, but understanding risk builds confidence.
By listening, by learning from countries lived experience of these technologies over time, New Zealand can make informed decisions and avoid history repeating.
The choice is straightforward: allow hesitation to slow progress, or move forward with care, openness and preparation based on the learnings of those who have come before us.
Will New Zealand lead — or watch from the sidelines?
